Skip to main content
. 2022 Apr 27;9(5):e309–e322. doi: 10.1016/S2352-3018(22)00041-8

Figure 2.

Figure 2

Adverse events in the 7 days after the first and second doses in HIV-negative people and people living with HIV-1, stratified by baseline SARS-CoV-2 status

(A) Local adverse events in HIV-negative participants. (B) Systemic adverse events in HIV-negative participants. (C) Local adverse events in people living with HIV-1. (D) Systemic adverse events in people living with HIV-1. BL=baseline. NVX-CoV2373=5 μg SARS-CoV-2 recombinant spike protein with 50 μg Matrix-M adjuvant. *BL-positive refers to baseline seropositive or PCR-positive at any stage from enrolment to day 35.